Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: R. K. (Chip) Constantian Jr. who wrote (3141)	6/3/1998 2:24:00 AM
From: steve wong	Read Replies (1) \| Respond to of 9523

TO ALL: Even Better Bedtime Story! MUSE ineffective! Tuesday June 2, 8:28 pm Eastern Time Vivus impotence drug is ineffective in many - report By Mark Egan LOS ANGELES, June 2 (Reuters) - Vivus Inc.'s impotence drug MUSE is ineffective in most men when taken in a clinic and even less useful for those taking it at home, despite a 1997 study that showed it worked in most patients, researchers said on Tuesday. ''For a variety of possible reasons efficacy in a controlled clinical trial has not translated into clinical usefulness of the MUSE system for the majority of our patients suffering from erectile dysfunction,'' Dr. Pat Fulgham wrote in a presentation made at the American Urological Association's annual meeting in San Diego. Fulgham, of the Presbyterian Hospital in Dallas, told reporters on a conference call that only 27 percent of patients in his study achieved sufficient erections for sexual intercourse despite higher doses. Vivus officials did not return calls for comment. Impotence is the persistent inability to achieve or maintain an erection sufficient for sexual performance and affects more than 30 million men in the United States. The trial of 115 male patients, aged 65 on average, who suffered from impotence was begun after doctors found that the reported efficacy of MUSE was not translating into effective treatment in patients taking the drug in their clinics. Since the doctors were disappointed with the results they were getting in their patients they undertook a study designed to mimic the New England Journal of Medicine report on the drug which showed it to be effective in most patients. That 1997 study of MUSE, an acronym for medicated urethral system for erection, said that 65.9 percent of men administered MUSE in the clinic achieved an erection sufficient for intercourse. It further said that 64.9 percent of men who took MUSE at home had intercourse at least once. Patients in Fulgham's trial were administered MUSE in the clinic and only 27 percent gained an erection sufficient for intercourse, he said. Follow-up revealed that only 18.6 percent of the patients continued using the treatment at home. Fulgham said difficulty in using the MUSE system in the absence of a medical professional may have contributed to the drop off in those using the treatment at home. MUSE is a dose of the drug alprostadil in the form of a pellet. Patients insert a plastic applicator into the tip of their penis dispensing the pellet. An erection should develop within 10 minutes and last for 30 to 60 minutes. Earlier Vivus said a separate MUSE presentation made at the conference showed the treatment to be safe in patients with severe erectile dysfunction. Menlo Park, Calif.-based Vivus has been fighting to convince the public that its MUSE is better than Pfizer Inc.'s much hyped drug Viagra, the first oral pill for impotence. Vivus has maintained that its treatment is more effective in men with severe impotence than Viagra. But another report at the San Diego meeting on Tuesday claimed Viagra was effective in half of men with the most severe impotence problems which suggests Viagra could further erode Vivus' market. Since its launch in April more than 1.5 million prescriptions for Viagra have been written making it one of the most popular drugs ever in the United States.